Dedicated to the memory of Natalie Grover, who co-created the Women in Biopharma R&D special report while she was a reporter ...

Global investment manager Oaktree is out with its third life sciences-dedicated special purpose acquisition company after ...

Kezar Life Sciences’ autoimmune drug candidate, zetomipzomib, has been put on hold by the FDA after the company said last ...

Upstream Bio, a mid-stage respiratory drug developer, and CAMP4 Therapeutics, a Phase 1 regulatory RNA startup, have unveiled ...

The activist investor Starboard Value has taken a stake in Pfizer, according to media reports, following the drugmaker's months of lackluster results as it came out of the pandemic and sought the next ...

Alnylam Pharmaceuticals has agreed to drop its 2023 patent lawsuit against Moderna in a Delaware court following a judge's ...

Andrew Miller has quickly made his first move after the technology he invented, KarXT, secured an FDA approval last week. The ...

This season’s uptake of RSV vaccines in the US has been slower than expected, according to Wall Street analysts tracking ...

Wave Life Sciences brought in $230 million through an upsized public offering, extending its cash runway into 2027 as a ...

The Center for Biomedical Advanced Research and Development Authority (BARDA) is giving $72 million to three drugmakers to ...

The European Medicines Agency is looking more closely at medicines used to treat hair loss and a condition caused by an ...

What’s left of Johnson & Johnson’s infectious disease work continues to shrink, after the company announced Friday that it ...